ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Conversation with The Cancer Letter: Scott Soefje: “These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?”

October 3, 2014

Broder, Herberman, Decline To Coauthor Reanalysis of Data

September 9, 1994

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012

In Brief: Comis Named ECOG Chairman; Long Joins Capitol Associates; Chabner Day In Shelbyville

April 14, 1995

Harvest Yet To Come From Radiotherapy Advances, Kaplan Tells NCAB

October 17, 1975

NCCS Networker Volume 1 Issue 1, March 1987

March 12, 1987